January Emerging Medical Technologies Report

Published January 2012 | 101 Pages | 47 Exhibits |


Order individually or subscribe and get a complete intel platform.


This report includes details on 47 emerging medical technology companies that have been identified by LSI's in-house research team in January 2012.

All companies include technology, market(s), key executive, and contact information.

Two- to three-page executive summaries are provided on most of the companies. Executive summaries typically include:

• Company Contact Information
• Company Overview (structure, size, year founded, etc.)
• Competitive Landscape
• Technological Advantage
• Stage of Development
• Target Markets
• Financial Summary and Sales Forecasts
• Financing & Partnering Needs
• IP Position & Status
• Management Team
• Exit Strategy
• More

Coverage includes innovations in a broad spectrum of medical technology areas including:
- Aesthetics/Dermatology Companies
- Biomaterials Companies
- Biotechnology/Cell Therapy Companies
- Cardiovascular Companies
- Dental Companies
- Diagnostics Companies
- Drug Delivery Companies
- Endocrine Companies
- Gastroenterology Companies
- Gynecology/Women's Health Companies
- Imaging Companies
- Neurology Companies
- Oncology Companies
- Ophthalmology Companies
- Orthopedics Companies
- Pain Management Companies
- Patient Management/Monitoring Companies
- Pharmaceutical Companies
- Respiratory Companies
- Spine Companies
- Surgery Companies
- Urology Companies
- Vascular Companies
- Wound Management Companies

This report is included in LSI's Emerging Medical Technologies® Database.

Table of Contents


• A battery-powered device which lifts and acquires a healthcare patient weighing up to 500 lbs. - without any caregiver's touching, logrolling, or lifting - and transports them to the next destination, then gently discharges them onto the desired horizontal surface
• A bionic retina designed to restore sight to millions blinded by retinal degenerative diseases
• A molecular diagnostics test that examines somatic alterations in cancer-related genes by applying massively parallel sequencing to routine clinical specimens, enabling targeted therapy
• A nanotechnology-enabled portfolio of therapeutic products for use in medical applications
• A next-generation eye drop medication that uses Rho-kinase inhibitors to treat glaucoma
• A novel annuloplasty ring for heart valve repair. The Intra-annular Ring represents a unique solution for children allowing the valve to grow following implantation.
• A range of injectable gels made from hyaluronic acid for applications in Aesthetic Dermatology, Ophthalmology, and Orthopaedics
• An aerosolized long-acting muscarinic antagonist that treats chronic obstructive pulmonary disease (COPD)
• An inhaler with variable dosage of Asthma medicine, based on a built-in exhaling measurement of the airway obstruction level
• An oral delivery platform for medications, food supplements, and other soluble substances that is easy-to-use, friendly, inexpensive, and requires no third-party assistance
• Electronic stimulation technologies that maintain muscle strength during recovery in the intensive care unit or other periods of inactivity
• Endoear(R) is the world's first implantable hearing device of its kind, created for the treatment of mild to moderate hearing loss
• Implantable drug delivery device using nanochannel-based chip to control/modulate release
• Implantable vagus nerve stimulation system for the treatment of tinnitus and post-stroke motor rehabilitation
• Innovative central nervous system therapies; Allon is proceeding in a fully enrolled pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP)
• Innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders such as migraine, Parkinson's disease, schizophrenia, and bipolar disorder
• Innovative new topical therapies for dermatology applications, including photodynamic therapy for sebaceous gland disorders and small molecule therapeutics that treat acne, inflammatory skin diseases, and sebaceous gland hyperactivity
• Long-acting, intravenous lipoglycopeptide used to treat acute bacterial skin and skin structure infections
• Micro-format, CMOS-based, imaging technology for minimally-invasive, disposable endoscopic medical procedures
• Nanofibers designed for use in tissue engineering, drug delivery, and wound care
• New gene-based medicines to treat "dominant" genetic diseases, particularly for the eye
• Non-invasive, rapid, quantitative measurement of metabolic health of the retina using a novel spectroscopic biomarker
• Novel drugs that treat cancer by targeting cellular protein homeostasis pathways
• Novel metal abstraction peptide (MAP) platform technology that delivers platinum to cancer cells by incorporating it into cancer-targeting proteins, thereby improving treatment while limiting side effects and damage to healthy cells
• Novel, minimally invasive surgical devices for the treatment of sinusitis
• Oncology drugs that utilize novel mechanisms of action
• Products for minimally invasive bypass surgery
• Proprietary technology for decellularizing biological organs/tissues to create an extra-cellular matrix retaining its original architecture, mechanical properties, and vascular network - suitable for scaffold transplantation or growing new functional organs/tissues by recellularization
• Pro-Vas is a novel less-invasive alternative to vasectomy for men seeking permanent contraception
• Ready-to-market medical device for assessing - via the eye - exposure to neurotoxins, cyanide, and low level radiation. Future products include assessment of mild TBI and other health conditions, including diabetic diseases of the eye.
• Real-time, non-contact, high resolution tissue temperature monitoring & mapping products that improve the safety and efficacy of ablation therapy by avoiding injury to surrounding tissue
• Requiring only one drop of blood, the proprietary LBIdx(TM) Plasma Thermogram(TM) tests will significantly improve the clinical diagnosis and monitoring of autoimmune disease and cancer, vastly improving patient outcomes
• Sutureless, adjustable mitral annuloplasty toolset for surgical and robotic procedures
• Technology that has demonstrated its usefulness in tracking all facets of in vivo oxygen metabolism using normally installed MRI scanners
• Technology that provides an immediate cardiovascular risk prediction for major chronic diseases, such as diabetes. The method is convenient, easy-to-use, and validated. It measures tissue accumulation of Advanced Glycation End products (AGEs) by means of fluorescence techniques. AGEs play a key role in the pathogenesis of many age-related diseases, such as diabetes and cardiovascular disease.
• The fentanyl iontophoretic transdermal system (IONSYS), an investigational, pre-programmed drug delivery system comprising a compact, needle-free, self-contained system that provides patient-controlled analgesia for adult inpatients requiring post-operative opioid therapy
• The first home-based telemonitoring system for patients with age-related macular degeneration, the leading cause of blindness in people over age 50 in the western world
• The patented EXMI technology uses pulsed magnetic fields that penetrate up to 7,5 cm into the body, stimulating nerves (neuromodulation), contracting muscles (rehabilitation), treating pain/depression, and increasing blood flow
• The Renaissance(TM) Surgical Guidance System is transforming spine surgery from freehand procedures to highly-accurate, state-of-the-art operations that raise the standard of care with better clinical outcomes
• The RGS Vertex360(TM), which competes with the Gamma knife in the non-invasive treatment of brain tumors, is a highly precise cobalt 60 radiation system that utilizes the OsiriX(TM) based Explorer 4D(TM) treatment planning system, also developed by the company
• The Rx Timer Cap is a patented "smart cap" with a built-in LCD timer that fits common prescription vials and lets patients know exactly how long it has been since they last took their medication
• Third-generation transcatheter aortic valve prosthesis with increased safety, greater ease-of-use, and longer durability
• Two novel technologies that boost immune responses, including a synthetic toll-like receptor agonist for use as an adjuvant to vaccines , and a viral vector that targets immature dendritic cells
• Ultrasonic devices for non-invasive fat removal from the chin, arm, and eye-bags and for skin tightening
• Vaccine platform technology for cancer and infectious diseases based on Listeria monocytogenes that has been engineered to be safe for use in humans and express and specific disease antigens
• Vascular closure device that seals the femoral artery following cardiac catherization
• Ventritek 105 is a novel medical device that provides full treatment for Stroke/SAH/ICH patients by replacing the current long and risky procedure

Ready to get started?

We help you make smarter decisions and form stronger partnerships through curated events, independent market intelligence products and services, and digital-forward media.